Product Description
PF-03635659 is a potent, very long dissociative half-life (slow off-rate, >1440 min) muscarinic M3 antagonist. (Sourced from: https://drugs.ncats.io/drug/O0RG3QM34H)
Mechanisms of Action: M3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Chronic Obstructive Pulmonary Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00864786 |
B0431002 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2009-03-01 |
2019-03-18 |
Treatments |
|
2009-014540-11 |
2009-014540-11 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2010-06-15 |
2022-03-13 |
Treatments |
|
NCT01033487 |
B0431010 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2010-06-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|